Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Stellbrink, C
Right arrow Search for Related Content
PubMed
Right arrow Articles by Stellbrink, C
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Implantable card ioverter-defibrillators with or without cardiac resynchronization therapy — multiple therapy in a single device: a review with special reference to the PACIVIAN study

C Stellbrink*,1, A.-M Sinha1, B Diem1, A Auricchio2, S Boccanelli3, J Brugada4, H Klein2, J Morgan5, L Padeletti6, E Aliot7 and P Hanrath1 on behalf of the PACMAN Investigators

a Rheinisch-Westfälische Technische Hochschule, Aachen, Germany
b Otto-Guericke Universität, Magdeburg, Germany
c San Giovanni Hospital, Rome, Italy
d Cardiovascular Institute, Hospital Clinic, Barcelona, Spain
e Southampton General Hospital, Southampton, U.K.
f Ospedale Careggie OTC, Firenze, Italy
g Hôpital Central, Nancy, France

* Correspondence: Christoph Stellbrink, MD FESC, Medizinische Klinik I, RWTH Aachen, Pauwelsstrasse 30, D-52057 Aachen, Germany.

Abstract

Patients with heart failure and ventricular conduction disturbance benefit haemodynamically from cardiac resynchronization therapy (CRT), but reduced mortality with CRT has not been demonstrated. The implantable cardioverter-defibrillator (ICD) reduced sudden death, which accounts for more than 50% of heart failure mortality. This review focuses on data from trials on ICD and CRT treatment in heart failure patients. The design of one study — the Pacing in Cardiomyopathies, a European Study (PACMAN) — is presented. Current recruitment in this trial indicates that 30% of patients receiving CRT require ICD backup. Ongoing larger trials will determine the true benefit of ICD and CRT in heart failure patients.

Key Words: Cardiac resynchronization therapy • heart failure • implantable defibrillator


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.